AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Barclays Raises Price Target for Addus HomeCare (ADUS)
ByAinvest
Tuesday, Aug 19, 2025 7:39 pm ET1min read
Barclays raised the price target for Addus HomeCare (ADUS) from $83 to $109, a 31.33% increase. The analyst maintained the "Underweight" rating. Other analysts have raised price targets and maintained "Buy" ratings. The average target price is $140.55, with a high estimate of $160 and a low of $109. The average brokerage recommendation is 1.8, indicating "Outperform" status. GF Value estimates a one-year fair value of $132.84, suggesting a 16.33% upside from the current price.
Barclays has raised the price target for Addus HomeCare (ADUS) from $83 to $109, a 31.33% increase, while maintaining an "Underweight" rating [1]. This move comes as other analysts have also raised their price targets and maintained "Buy" ratings for the company. The average target price is now $140.55, with a high estimate of $160 and a low of $109. The average brokerage recommendation is 1.8, indicating an "Outperform" status. GF Value estimates a one-year fair value of $132.84, suggesting a 16.33% upside from the current price.Analysts' ratings and price targets provide valuable insights into the market's perception of Addus HomeCare. For instance, TD Cowen analyst Ryan Langston raised the price target to $139 from $135, citing positive fundamentals and additional revenues/EBITDA from the Helping Hands segment [1]. JMP Securities analysts have maintained their "Buy" rating with a price target of $150, highlighting the company's strong growth prospects [1].
Addus HomeCare operates in the home care services sector, providing personal care, hospice, and home health services. The company's revenue growth over the past three months has been significant, with a 21.79% increase, outperforming industry averages [2]. Additionally, the company's net margin and return on equity (ROE) are above industry benchmarks, indicating strong financial health [2].
While analyst ratings can influence investment decisions, it is crucial for investors to consider the company's fundamentals and their own risk tolerance. The recent analyst actions reflect a positive outlook on Addus HomeCare, but investors should conduct their own research and make informed decisions.
References:
[1] https://intellectia.ai/news/stock/barclays-maintains-underweight-on-addus-homecare-raises-price-target-to-109
[2] https://www.benzinga.com/insights/analyst-ratings/25/08/47207246/forecasting-the-future-5-analyst-projections-for-addus-homecare
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet